Clinical trial · Observational
Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan
Observational Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan
NCT02977312CI-TRIAL-00024949CCMLJcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study assessed the efficacy and safety of generic imatinib in patients with chronic myeloid leukemia (CML) in Jordan. It was a multicenter, non-interventional, open-label, prospective study combined with retrospective data collection from files of patients with a diagnosis of Ph+ CML, treated with Cemivil (imatinib), where no visits or intervention(s) additional to the daily practice were performed
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukemia, Chronic Phase | Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Imatinib | Drug | Imatinib | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Rate of Complete Cytogenetic Response (CCyR)
- timeFrame
- 12 months
- measure
- Rate of Major Molecular Response (MMR)
- timeFrame
- 12 months
Secondary outcomes (1)
- measure
- Incidence of treatment-emergent adverse events (AEs)
- timeFrame
- 12 months
- description
- (Safety \& Tolerability)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years * Newly diagnosed patients with Ph+ CML in CP; or CML patients who started with Cemivil treatment since its registration in Jordan and who confirmed CHR * Written informed consent Exclusion Criteria: * Age \<18 years * CML in accelerated phase * CML in blast crisis * CML with mutation(s) in the BCR-ABL gene * Contraindications to the administration of the study drug according to the approved Summary of Product Characteristics (SPC)
References
Publications (0)
Data not yet available
No reference posted for this study.